Skip to content
Other

2029

Amgen 2029 decreased by 17.9% to $2.3B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 17.9%, from $2.8B to $2.3B.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
Metric ID: other_finite_lived_intangible_assets_amortization_expens_a9462e

Historical Data

15 periods
 Q2 '21Q3 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$2.4B$2.4B$2.4B$2.4B$2.2B$2.2B$2.1B$2.1B$3.9B$3.9B$3.9B$2.8B$2.9B$2.8B$2.3B
QoQ Change+0.0%+0.0%+0.0%-8.3%+0.0%-4.5%+0.0%+85.7%+0.0%+0.0%-28.2%+3.6%-3.4%-17.9%
YoY Change+0.0%-8.3%-8.3%-12.5%-4.5%+77.3%+85.7%+85.7%-28.2%-25.6%-28.2%-17.9%
Range$2.1B$3.9B
CAGR-1.2%
Avg YoY Growth+9.6%
Median YoY Growth-8.3%
Current Streak2 quarters decline

Frequently Asked Questions

What is Amgen's 2029?
Amgen (AMGN) reported 2029 of $2.3B in Q1 2026.
How has Amgen's 2029 changed year-over-year?
Amgen's 2029 decreased by 17.9% year-over-year, from $2.8B to $2.3B.